Protein C News and Research

RSS

Cylene Pharmaceuticals to report recent developments of CX-4945 inhibitor at CK2 International Conference

Cylene Pharmaceuticals, Inc. will report recent developments with its first-in-class, oral CK2 inhibitor CX-4945, at the 6th International Conference on Protein Kinase CK2, to be held on September 7-10 in Cologne, Germany, the company announced today.

9 Sep 2010

Zyngenia completes $15M Series A financing extension from NEA

Zyngenia, Inc., a privately held biotherapeutics company focused on next-generation antibody drug development, announced today the completion of a $15 million Series A financing extension from New Enterprise Associates (NEA), one of the world's leading venture capital firms. The capital will be used to continue to rapidly progress Zyngenia's pipeline of Zybodies™, which are novel, multi-specific, antibody-based molecules that address two or more biological targets with a single protein drug.

8 Sep 2010

Champions Biotechnology signs agreement to test Cephalon's CEP-32496 in Biomerk Tumorgraft platform

Champions Biotechnology, Inc., an oncology drug development company with a predictive preclinical platform aimed at accelerating the development and enhancing the value of oncology drugs, announced the establishment of an agreement with Cephalon, Inc., a global biopharmaceutical company, for the testing of the Cephalon novel B-Raf inhibitor CEP-32496 in Champions' Biomerk Tumorgraft™ platform.

8 Sep 2010

Trius Therapeutics announces presentations from drug development programs at 50th ICAAC

Trius Therapeutics, Inc. announced today that the results of multiple studies from its drug development programs, including its lead antibiotic drug candidate torezolid phosphate (TR-701), will be presented in poster presentations at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) meeting in Boston September 12-15.

8 Sep 2010

ImmuneRegen's Homspera with Scancell's ImmunoBody technology improves immune response for cancer

ImmuneRegen BioSciences, Inc., a wholly owned subsidiary of IR BioSciences Holdings, Inc. today announced that treatment with its lead compound, Homspera, in combination with a DNA vaccine utilizing Scancell's ImmunoBody technology significantly improved the immune response of the vaccine in an animal model.

8 Sep 2010

PPTA supports CMS' proposal for hospital outpatient reimbursement for plasma protein therapies

The Plasma Protein Therapeutics Association (PPTA) recommends that the Centers for Medicare and Medicaid Services (CMS) finalize its Proposed Rule regarding reimbursement to better ensure patient access to vital medicines in the hospital outpatient setting.

8 Sep 2010

Progerin may contribute to risk of atherosclerosis: Study

Progeria, also known as Hutchinson-Gilford Progeria Syndrome (HGPS), is a rare, fatal genetic disease characterized by an appearance of accelerated aging in children. All children with Progeria die of the same heart disease that affects millions of normal aging adults (atherosclerosis), but instead of occurring at 60 or 70 years of age, these children may suffer heart attacks and strokes even before age 10, and the average age of death is 13 years.

8 Sep 2010

Octapharma announces new study of IVIG in chronic inflammatory demyelinating polyradiculoneuropathy

Octapharma AG today announced the imminent start of the biggest ever study of an intravenous immunoglobulin preparation (IVIG) in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP).

8 Sep 2010

Scientists study behaviour of proteins that trigger age-related ailments

Scientists hope to gain insights into a range of age-related ailments, such as dementia, by examining the behaviour of proteins thought to trigger the conditions.Researchers from the University of Edinburgh are to study proteins found in the body to try to find out why these molecules can sometimes clump together as people get older. The clumps interfere with the biological processes that enable the body to function healthily.

8 Sep 2010

Silence Therapeutics receives two patents for RNA interference therapeutics

Silence Therapeutics plc announces the issuance of two new patents by the United States Patent and Trademark Office (USPTO) which are broadly directed to double-stranded short interfering RNA (siRNA) sequences against the validated cancer targets epidermal growth factor receptor related protein (EGFR-RP) and vascular endothelial growth factor receptor 1 (VEGFR1).

8 Sep 2010

Researchers discover tolerance mechanism in chronic morphine treatment

Researchers from Mount Sinai School of Medicine have discovered a major mechanism underlying the development of tolerance to chronic morphine treatment. The discovery may help researchers find new therapies to treat chronic pain, and reduce tolerance and side effects associated with morphine use. The findings are published in the July 20th issue of Science Signaling.

8 Sep 2010

Quick increase of calcium concentration in cells rapidly trigger Aurora-A kinase enzyme activity

Aurora-A kinase (AurA) is an enzyme that is hyperactive in many cancers and drives tumor cell proliferation. Several AurA inhibitors are currently being tested in clinical trials to see if they slow tumor growth. Now, researchers in the Developmental Therapeutics Program at Fox Chase Cancer Center have identified an activation signal for AurA. They report in the September 7 issue of Nature Communications that a quick increase in the calcium concentration in a cell rapidly triggers AurA kinase activity.

8 Sep 2010

Study finds increase in bone morphogenetic protein usage for Off-Label procedures

Bone morphogenetic protein (BMP) is increasingly used as an alternative to the patient's own bone for spinal fusion surgery. Yet at least 85 percent of these procedures are operations for which BMP use has not been formally approved by the U.S. Food and Drug Administration (FDA), suggests a study in the September 1 issue of Spine.

8 Sep 2010

Bristol-Myers Squibb signs definitive agreement to acquire ZymoGenetics

Bristol-Myers Squibb Company and ZymoGenetics, Inc. announced today that the companies have signed a definitive agreement providing for the acquisition of ZymoGenetics by Bristol-Myers Squibb, for $9.75 per share in cash.

8 Sep 2010

Researchers develop new RNA molecule approach to kill cancer cells

Researchers at the California Institute of Technology (Caltech) have engineered a fundamentally new approach to killing cancer cells. The process developed by Niles Pierce, associate professor of applied and computational mathematics and bioengineering at Caltech, and his colleagues uses small RNA molecules that can be programmed to attack only specific cancer cells then, by changing shape, those molecules cause the cancer cells to self destruct.

8 Sep 2010

Yeast can be simple model to study molecular basis of Parkinson’s disease

Yeast could be a powerful ally in the discovery of new therapeutic drugs to treat Parkinson's disease says a scientist presenting his work at the Society for General Microbiology's autumn meeting in Nottingham today.

8 Sep 2010

CytRx commences PROACT Phase 2 clinical trial of bafetinib for advanced prostate cancer

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced initiation of the PROstate Advanced Cancer Treatment (PROACT) Phase 2 proof-of-concept clinical trial to evaluate the efficacy and safety of bafetinib in patients with advanced prostate cancer.

7 Sep 2010

Promedior initiates PRM-151 Phase 2a clinical study in prevention of scarring post glaucoma filtration surgery

Promedior, Inc., a clinical stage biotechnology company developing novel therapies to treat fibrotic and inflammatory diseases, announced today that it has initiated a Phase 2a clinical study of PRM-151 to evaluate the efficacy, safety, and tolerability of PRM-151 in preventing post-surgical scarring in glaucoma patients following glaucoma filtration surgery. There currently are no approved drugs for preventing post-surgical scarring in glaucoma, and there are no approved anti-fibrotic drug therapies in the U.S. or Europe for any fibrotic disease.

7 Sep 2010

University of Maryland School of Medicine orders AVANCE III 950 US2 NMR spectrometer from Bruker

Bruker Corporation announces a major order from the University of Maryland School of Medicine for its ultra-high field AVANCE III 950 US2 NMR spectrometer. The 950 MHz Nuclear Magnetic Resonance magnet and spectrometer will help University of Maryland researchers to unravel the mysteries of molecules and develop new agents to treat cancer, AIDS and other diseases.

7 Sep 2010

Bruker announces NIST order for AVANCE III 900 NMR spectrometer

Bruker Corporation, the leader in analytical magnetic resonance instrumentation, today announces a major order from the National Institute of Standards and Technology (NIST) for its ultra-high field AVANCE™ III 900 US2 NMR spectrometer.

7 Sep 2010

Protein C News and Research

Cylene Pharmaceuticals to report recent developments of CX-4945 inhibitor at CK2 International Conference

Zyngenia completes $15M Series A financing extension from NEA

Champions Biotechnology signs agreement to test Cephalon's CEP-32496 in Biomerk Tumorgraft platform

Trius Therapeutics announces presentations from drug development programs at 50th ICAAC

ImmuneRegen's Homspera with Scancell's ImmunoBody technology improves immune response for cancer

PPTA supports CMS' proposal for hospital outpatient reimbursement for plasma protein therapies

Progerin may contribute to risk of atherosclerosis: Study

Octapharma announces new study of IVIG in chronic inflammatory demyelinating polyradiculoneuropathy

Scientists study behaviour of proteins that trigger age-related ailments

Silence Therapeutics receives two patents for RNA interference therapeutics

Researchers discover tolerance mechanism in chronic morphine treatment

Quick increase of calcium concentration in cells rapidly trigger Aurora-A kinase enzyme activity

Study finds increase in bone morphogenetic protein usage for Off-Label procedures

Bristol-Myers Squibb signs definitive agreement to acquire ZymoGenetics

Researchers develop new RNA molecule approach to kill cancer cells

Yeast can be simple model to study molecular basis of Parkinson’s disease

CytRx commences PROACT Phase 2 clinical trial of bafetinib for advanced prostate cancer

Promedior initiates PRM-151 Phase 2a clinical study in prevention of scarring post glaucoma filtration surgery

University of Maryland School of Medicine orders AVANCE III 950 US2 NMR spectrometer from Bruker

Bruker announces NIST order for AVANCE III 900 NMR spectrometer

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News